AtriCure (NASDAQ:ATRC) Insider Salvatore Privitera Sells 7,763 Shares

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 7,763 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $52.50, for a total value of $407,557.50. Following the completion of the transaction, the insider directly owned 150,921 shares of the company’s stock, valued at $7,923,352.50. This trade represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AtriCure Trading Down 1.8%

Shares of ATRC stock opened at $51.52 on Friday. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $53.50. The firm has a market capitalization of $2.62 billion, a PE ratio of 245.35 and a beta of 1.26. The stock has a fifty day moving average of $40.10 and a two-hundred day moving average of $32.83. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the previous year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts expect that AtriCure, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on ATRC shares. BTIG Research increased their price target on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 24th. Piper Sandler upped their price objective on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. UBS Group decreased their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, Needham & Company LLC boosted their price target on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $52.00.

Institutional Trading of AtriCure

Large investors have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. purchased a new position in shares of AtriCure during the second quarter valued at $37,000. Harbor Investment Advisory LLC purchased a new position in AtriCure during the 2nd quarter valued at about $40,000. Allworth Financial LP purchased a new position in AtriCure during the 2nd quarter valued at about $43,000. Smartleaf Asset Management LLC increased its holdings in shares of AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the period. Finally, Fifth Third Bancorp acquired a new position in shares of AtriCure in the 1st quarter valued at about $51,000. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.